Ticker brief
NVS NOVARTIS AG-SPONSORED ADR
Consumer, Non-cyclical · Pharmaceuticals
last close
$153.81
1 day
-0.5%
14 days
+1.9%
mkt cap
$305.1B
signals 14d
11
authors 14d
8
crowd 14d
+1.0σ
Options inteloptions-surface reads · latest available day per source
| metric | reading | context |
|---|---|---|
| IV — ATM 30d | 34% rich · 100 pctile own 1y | IV/HV 1.22× |
| Skew — 25Δ RR 30d | -0.004 94 pctile own 1y | calls bid vs puts (call skew rich) |
| Net dealer OI (NDOI) | +0.01 thin | 5-session Δ -0.00 (as of 2026-07-06) |
| OI alarm | quiet | last alarm 2026-02-04 (z=3.0) |
| CSP screen | rank #2 · $147.9 strike · 0.53% prem | on the CSP screen (2026-08-28) |
Sentiment — last 14 days
daily mean sentiment, 2026-08-17 → 2026-08-26 · now +0.27 (−1 bearish … +1 bullish)
Who spoke8
| author | grade | trader score | signals | mean sent |
|---|---|---|---|---|
| @bioinvestor24 | A | -0.45 | 4 | +0.01 |
| @TalkMarkets | C | · | 1 | +0.35 |
| @_TP888 | C | -1.12 | 1 | -0.65 |
| @kiantrades | C | +0.69 | 1 | -0.60 |
| @fwpharma | B | +0.98 | 1 | +0.10 |
| @PersimmonTI | A | -0.57 | 1 | +0.20 |
| @adamfeuerstein | A | +1.41 | 1 | +0.20 |
| @Biomaven | A | +1.79 | 1 | +0.35 |
Recent signals11of 11 in 14d — receipts included
| date (PT) | author | sent | what they said | since then | receipt |
|---|---|---|---|---|---|
| 2026-08-26 | @Biomaven | +0.35 | Calls the field a major opportunity and sees Lilly as the likely winner, with Novartis reading out first. | -2.4% | tweet ↗ |
| 2026-08-26 | @adamfeuerstein | +0.20 | Frames NVS, AMGN and LLY as contenders in a multibillion-dollar Lp(a) drug-development race. | -2.4% | tweet ↗ |
| 2026-08-23 | @bioinvestor24 | +0.25 | Speculates Novartis could pursue Syre as a needed immunology acquisition and eventually resemble BMY. | -3.2% | tweet ↗ |
| 2026-08-23 | @PersimmonTI | +0.20 | Interprets research after NVO's ZEUS failure and proposes Lp(a)-stratified inflammation analysis. | -3.2% | tweet ↗ |
| 2026-08-19 | @fwpharma | +0.10 | Reports Novartis joining a €97M Kynexis funding round. | -4.1% | tweet ↗ |
| 2026-08-18 | @bioinvestor24 | +0.05 | Views EWTX as a possible Entresto replacement and acquisition candidate, while noting early-data risk. | -0.5% | tweet ↗ |
| 2026-08-18 | @bioinvestor24 | -0.10 | Disagrees with a claim by noting NVS has had several BCR-ABL inhibitors. | -0.5% | tweet ↗ |
| 2026-08-18 | @bioinvestor24 | -0.15 | NVS loss-of-exclusivity needs support; EWTX and ELVN are framed as strategic-fit candidates. | -0.5% | tweet ↗ |
| 2026-08-18 | @kiantrades | -0.60 | Reports notable bullish call flow and bearish put flow with strikes, expiries and premiums. | -0.5% | tweet ↗ |
| 2026-08-18 | @_TP888 | -0.65 | Reports 99% ask-side put buying with $1.09M premium. | -0.5% | tweet ↗ |
| 2026-08-17 | @TalkMarkets | +0.35 | Attributes portfolio gains to a basket of large-cap biopharma holdings. | +1.2% | tweet ↗ |
“Since then” = price move from the close on the signal's date (PT) to the latest close — what happened after they said it, not a backtest. A — means no trading session has closed since the signal yet. Sentiment is our extracted per-tweet score, −1…+1.